Volrustomig
Multispecific antibody
Also known as MEDI5752
Evidence outlook · lead readout
eVOLVE-Lung02 (NCT05984277) · Metastatic Non-small Cell Lung Cancer
The lead readout missed its primary endpoint. The grade and rationale below record what the trial was designed to show and what it found.
eVOLVE-Lung02 (NCT05984277): eVOLVE-Lung02 was a randomized, open-label Phase 3 in 895 participants with metastatic non-small cell lung cancer with progression-free and overall survival as dual primary endpoints. An independent committee judged at an interim review that neither endpoint was likely to be met, and the sponsor stopped the trial. A randomized but open-label trial with a negative result is moderate evidence of no benefit.
Also in development:Cervical Cancer · Phase 3Head and Neck Squamous Cell Carcinoma · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
eVOLVE-Lung02 NCT05984277 · Metastatic Non-small Cell Lung Cancer eVOLVE-Lung02 was a randomized, open-label Phase 3 in 895 participants with metastatic non-small cell lung cancer with progression-free and overall survival as dual primary endpoints. An independent committee judged at an interim review that neither endpoint was likely to be met, and the sponsor stopped the trial. A randomized but open-label trial with a negative result is moderate evidence of no benefit. Registry: NCT05984277 | 3 | Progression-Free Survival (PFS) (using BICR assessments according to RECIST 1.1) (Up to approximately 6 years); Overall Survival (OS), in PD-L1-negative participants. (Up to approximately 6 years) 2026-08-17 | Dual primary endpoints (PFS and OS) not expected to be met: the IDMC concluded the volrustomig combination was unlikely to meet either, and AstraZeneca is discontinuing the trial (2026-08-17). | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (4)
What this study did
What this study did
What this study did
What this study did
Phase 2 (12)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (10)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other PD-1 x CTLA-4 drugs
Iparomlimab and tuvonralimab, Danvilostomig, Lorigerlimab, AI-061. Compare all 5 PD-1 x CTLA-4 drugs
4 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Cervical Cancer: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Volrustomig: this drug | Phase 3 | Multispecific antibody | PD-1 x CTLA-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | not yet graded | No reviewed efficacy summary in this indication | |
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Jobevne (bevacizumab-Nwgd) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Reliable signal | No reviewed efficacy summary in this indication | |
| Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex) | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Tisotumab Vedotin Humax-Tf-Adc (Tivdak) | Approved | Antibody–drug conjugate | Tissue Factor (TF) | Partial signal | NCT04697628: Overall Survival (From randomization to date of death due to any cause or censoring date, whichever occurred first (maximum up to 25 months)): Tisotumab Vedotin 11.5 Months (95% CI 9.8 to 14.9) | Chemotherapy 9.5 Months (95% CI 7.9 to 10.7) NCT03438396: Percentage of Participants With Confirmed Objective Response (OR) as Assessed by the Independent Review Committee (IRC) (From Day 1 through IRC verified disease progression, initiation of new anticancer therapy, study withdrawal, or death, whichever occurred first (approximately 20 months)): Tisotumab Vedotin 23.8 Percentage of Participants (95% CI 15.9 to 33.3) | |
| Vegzelma (bevacizumab-Adcd) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Zirabev (bevacizumab-Bvzr) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Cadonilimab | Phase 3 | Multispecific antibody | PD-1×CTLA-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Enlonstobart | Phase 3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Famitinib | Phase 3 | Small molecule | c-Kit, VEGFR2 (KDR), PDGFRbeta, VEGFR3, FLT1, FLT3 | not yet graded | No reviewed efficacy summary in this indication | |
| Notiretatug Rezetecan | Phase 3 | Antibody–drug conjugate | Nectin-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Sacituzumab Tirumotecan | Phase 3 | Antibody–drug conjugate | TROP2 | not yet graded | No reviewed efficacy summary in this indication | |
| Sutantatug Envedotin | Phase 3 | Antibody–drug conjugate | Nectin-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Camrelizumab | Phase 2/3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Balstilimab | Phase 2 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Lorigerlimab | Phase 2(overall) | Multispecific antibody | PD-1 x CTLA-4 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| ALE.P02 | Phase 1/2(overall) | Antibody–drug conjugate | Claudin-1 (CLDN1) | not yet graded | No reviewed efficacy summary in this indication | |
| GI-101A | Phase 1/2 | Protein / enzyme therapeutic | CTLA-4 / IL-2Rβγ | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(16 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Volrustomig to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (9)
January 2027 (1)
What to watch
May 2027 (1)
What to watch
June 2027 (2)
July 2027 (1)
What to watch
October 2027 (1)
What to watch
November 2027 (2)
December 2027 (1)
What to watch
2028 (3)
March 2028 (1)
What to watch
2029 (1)
August 2029 (1)
What to watch
2030 (2)
2031 (1)
December 2031 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent